MetaVia Inc. (NASDAQ: MTVA) reported new clinical data for its obesity drug candidate DA-1726 at the American Diabetes Association's 2026 Scientific Sessions held June 5-8 in New Orleans. The company presented results from a Phase 1 study showing the 48 mg dose achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau.

In the randomized, double-blind, placebo-controlled Phase 1 multiple ascending dose study, DA-1726 was administered once weekly via subcutaneous injection to obese but otherwise healthy adults. The 48 mg cohort showed a 6.1% reduction in body weight at Day 26 and 9.1% at Day 54, with statistical significance versus placebo at Day 26. Waist circumference decreased by 5.8 cm at Day 22 and 9.8 cm at Day 54.

DA-1726 is a dual agonist targeting glucagon-like peptide-1 receptors and glucagon receptors. The drug was generally well tolerated with predominantly mild-to-moderate and transient gastrointestinal adverse events. No treatment-related discontinuations or serious adverse events occurred in the 48 mg cohort.

MetaVia also presented preclinical data for its drug candidate vanoglipel, a G-protein-coupled receptor 119 agonist. In combination with resmetirom, vanoglipel demonstrated a 23.6% body weight reduction versus control in a mouse model of metabolic dysfunction-associated steatohepatitis. When combined with metformin in a diabetic mouse model, the combination reduced non-fasting glucose by 28.7% and achieved 16.3% body weight reduction versus control.

"DA-1726 demonstrated clinically meaningful and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau," said Hyung Heon Kim, President and Chief Executive Officer of MetaVia. The company expects results from ongoing Phase 1 Part 3 titration studies in the fourth quarter of 2026.